NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and operational inefficiencies that led to significant financial losses for investors during the specified class period [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that West Pharmaceutical misrepresented its visibility into customer demand and failed to disclose ongoing destocking issues in its High-Value Products portfolio, which negatively impacted profit margins [3]. - The company’s SmartDose device, initially positioned as a high-margin growth product, was revealed to be dilutive to profit margins due to operational inefficiencies [3]. - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion for 2025, which was significantly below market expectations, leading to a stock price drop of over 38% [4]. Group 2: Class Action Process - Investors who purchased West Pharmaceutical common stock during the class period have until July 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5]. Group 3: Company Background - West Pharmaceutical designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147325&from=4 CLAS ...

SAN DIEGO, May 7, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025. West is a medical supplies company that specializes in the development, manufacture, and distribution of elastomer-based supplies for the containment and administration of injectable drugs.For more information, submit a form, ...

Core Viewpoint - A securities class action lawsuit has been filed against West Pharmaceutical Services, Inc. for failing to disclose significant operational issues and misleading investors regarding the company's financial health during the class period from February 16, 2023, to February 12, 2025 [1] Group 1: Allegations Against the Company - The complaint alleges that the company did not disclose ongoing destocking issues in its high-margin High-Value Products portfolio, contrary to claims of strong visibility into customer demand [2] - It is claimed that the SmartDose device, positioned as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2] - The margin pressures led to risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [2] - Positive statements made by the company regarding its business and prospects were materially false or misleading [2] Group 2: Impact of Disclosures - The truth about the company's financial struggles was revealed on February 13, 2025, when it issued weak revenue and earnings forecasts for 2025 [3] - The company attributed its disappointing guidance to contract manufacturing headwinds and the loss of two major glucose monitoring customers transitioning to in-house manufacturing [3] - The SmartDose wearable injector devices were indicated to be margin-dilutive in 2025, prompting the company to consider various options to improve its economics [3] - Following these disclosures, the company's stock price fell by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [3]

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for potential securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves allegations against West and certain officers and/or directors regarding securities fraud or other unlawful business practices [2]. - Investors who purchased West securities during the Class Period can request to be appointed as Lead Plaintiff by July 7, 2025 [3]. Group 2: Financial Performance - On February 13, 2025, West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to challenges in its Contract Manufacturing segment [3]. - The company lost two major continuous glucose monitoring customers who transitioned to in-house manufacturing, which West did not participate in due to unmet financial thresholds [3]. - West's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the company to consider various options to improve its economics [3]. - Following the announcement, West's stock price dropped by $123.17 per share, or 38.2%, closing at $199.11 per share on February 13, 2025 [3].

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and operational inefficiencies impacting financial performance [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., and covers purchasers of West Pharmaceutical common stock from February 16, 2023, to February 12, 2025 [1]. - Investors have until July 7, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and the performance of its high-margin products [3]. Group 2: Allegations Against West Pharmaceutical - Allegations include that West Pharmaceutical was experiencing significant destocking in its High-Value Products portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, intended as a high-margin growth product, is claimed to be dilutive to profit margins due to operational inefficiencies [3]. - The company faced margin pressures that could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3]. Group 3: Financial Impact and Stock Performance - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion for 2025, which was significantly below market expectations [4]. - The disappointing guidance was attributed to losses of major customers transitioning to in-house manufacturing and the decision not to participate in future contracts due to unmet financial thresholds [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

Financial Data and Key Metrics Changes - The company reported net sales of $698 million for Q1 2025, representing an organic sales increase of 2.1% compared to the previous year [24][26] - Adjusted diluted EPS declined by 7.1% for Q1, but excluding stock-based compensation tax benefits, EPS improved by 1.4% [28] - Gross profit margin increased to 33.2%, up from 33.1% in Q1 2024, while adjusted operating profit margin rose to 17.9%, an increase of 20 basis points year-over-year [27][30] Business Line Data and Key Metrics Changes - Proprietary products business saw a 0.6% increase, with organic growth of 2.4%, driven by GLP-1s [11][26] - The biologics market unit delivered mid-single digit organic net sales growth, while the generics market unit declined mid-single digits [26] - Contract manufacturing segment experienced low single-digit net sales growth, primarily from self-injection devices for obesity and diabetes [18][26] Market Data and Key Metrics Changes - The HVP GLP-1 elastomer business grew to about 7% of total revenues in Q1 [11] - AnnexOne revenues contributed approximately 200 basis points to total revenues, exceeding expectations [14] - The company anticipates a high single-digit growth rate in biologics HVP components in the second half of 2025 [13] Company Strategy and Development Direction - The company is focused on capitalizing on competitive advantages in the GLP-1 market and enhancing margins through operational efficiencies [10][41] - A twofold strategy for the HVP delivery devices business includes driving margin improvement and evaluating the best path forward for the business [16] - The company is committed to investing in GLP-1 facilities and transitioning to drug handling for higher margins and lower capital intensity [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand outlook, noting an increase in demand and a positive trend in the biologics market [61][62] - The company is monitoring tariff impacts and has implemented strategies to mitigate costs, including passing some costs to customers [59][120] - Management indicated that while there are uncertainties, they do not foresee significant changes in demand due to government spending reductions [58][60] Other Important Information - The company announced executive leadership changes, including the departure of the CFO and the appointment of a new Senior Vice President [20][22] - The company is increasing its full-year 2025 revenue guidance to a range of $2.945 billion to $2.975 billion [34] - Capital expenditures for 2025 are guided at $275 million, unchanged from prior guidance [39] Q&A Session Summary Question: Utilization assumptions for the new site in Dublin - Management indicated that utilization is currently low as the site ramps up, which is incorporated into guidance [46] Question: Margin improvements in Q1 - Management noted better efficiencies in the E and PC business and improvements in contract manufacturing margins [48] Question: Guidance on high-value product growth - Management explained that pricing is slightly lower than anticipated and there are short-term supply constraints affecting growth [55] Question: Impact of tariffs and geopolitical factors - Management stated that they do not see significant changes in demand due to tariffs and have implemented strategies to mitigate costs [59][60] Question: Demand visibility and order trends - Management confirmed that order patterns are consistent with expectations and anticipate a sequential improvement throughout the year [138] Question: Pricing benefits related to SmartDose - Management clarified that no pricing benefits related to SmartDose are embedded in guidance at this time [121] Question: Operating margin guidance - Management did not provide specific operating margin guidance but indicated that they are targeting a return to higher margins over time [124]

Financial Performance - Consolidated net sales for the three months ended March 31, 2025, increased by $2.6 million, or 0.4%, to $698.0 million compared to $695.4 million in the same period in 2024, with an unfavorable foreign currency translation impact of $11.7 million[91] - Proprietary Products net sales increased by $3.5 million, or 0.6%, to $563.0 million for the three months ended March 31, 2025, while Contract-Manufactured Products net sales decreased by $0.9 million, or 0.7%, to $135.0 million[91][94] - Consolidated gross profit increased by $1.7 million, or 0.7%, to $231.9 million for the three months ended March 31, 2025, with a gross profit margin of 33.2% compared to 33.1% in the same period in 2024[95] - Adjusted operating profit for the three months ended March 31, 2025, was $125.0 million, with an adjusted net income of $106.2 million and diluted EPS of $1.45[87] - Consolidated operating profit decreased by $15.8 million, or 12.9%, for the three months ended March 31, 2025, including an unfavorable foreign currency translation impact of $2.6 million[110] - Adjusted consolidated operating profit increased by $2.0 million, or 1.6%, for the three months ended March 31, 2025, compared to the same period in 2024[110] Costs and Expenses - Consolidated R&D costs decreased by $1.3 million, or 7.4%, to $16.3 million for the three months ended March 31, 2025, primarily due to reduced salary and wages and a decrease in professional services[99] - Consolidated SG&A costs increased by $1.3 million, or 1.5%, to $88.0 million for the three months ended March 31, 2025, with SG&A as a percentage of net sales at 12.6%[101] - Proprietary Products SG&A costs decreased by $0.4 million, or 0.7%, for the three months ended March 31, 2025, compared to the same period in 2024[102] - Contract-Manufactured Products SG&A costs increased by $1.4 million, or 22.6%, for the three months ended March 31, 2025, primarily due to increased salary and wages[103] Cash Flow and Working Capital - Net cash provided by operating activities increased by $11.2 million for the three months ended March 31, 2025, primarily due to favorable working capital management[120] - Net cash used in investing activities decreased by $19.3 million for the three months ended March 31, 2025, due to a decrease in capital expenditures[121] - Cash and cash equivalents decreased to $404.2 million as of March 31, 2025, from $484.6 million as of December 31, 2024[122] - Working capital decreased by $56.9 million, or 5.8%, as of March 31, 2025, compared to December 31, 2024[124] - The total debt balance remained consistent at $202.6 million as of March 31, 2025[126] Taxation - The provision for income taxes increased to $24.1 million for the three months ended March 31, 2025, with an effective tax rate of 21.8%[118] Risks and Challenges - The company faces risks related to sales demand and its ability to meet that demand, which could impact unit volume, price, and profitability[136] - Competition from lower-cost producers in emerging markets may affect the company's market position and profitability[136] - Changes in customers' inventory requirements and manufacturing plans could alter existing orders or ordering patterns[136] - Supply chain interruptions, including extreme weather and natural disasters, may cause delivery delays or restrict the availability of raw materials[136] - The timely availability of filling capacity is essential for conducting stability trials and the commercialization of products[136] - The profitability of products sold may be affected by lower-than-expected sales growth of high-value proprietary offerings[136] - Dependence on third-party suppliers, including single-source suppliers, poses a risk to the company's operations[136] - The loss of key personnel or highly-skilled employees could impact the company's performance[136] - There have been no material changes in the company's exposure to market risk[139] - The company does not undertake any obligation to publicly update forward-looking statements unless required by law[138] Restructuring - The Company recorded restructuring charges of $17.8 million during the three months ended March 31, 2025, related to severance and other costs associated with its restructuring plan[93]

Financial Data and Key Metrics Changes - The company reported net sales of $698 million for Q1 2025, representing an organic sales increase of 2.1% compared to the previous year [24][26] - Adjusted diluted EPS declined by 7.1% for Q1, but excluding stock-based compensation tax benefits, EPS improved by 1.4% [28] - Gross profit margin increased to 33.2%, up from 33.1% in Q1 2024, while adjusted operating profit margin rose to 17.9%, an increase of 20 basis points year-over-year [27][30] Business Line Data and Key Metrics Changes - Proprietary products business saw a 0.6% increase, with organic growth of 2.4%, driven by GLP-1s [11][26] - The biologics market unit delivered mid-single digit organic net sales growth, while the generics market unit declined mid-single digits [26] - Contract manufacturing segment experienced low single-digit net sales growth, primarily from self-injection devices for obesity and diabetes [18][26] Market Data and Key Metrics Changes - The HVP GLP-1 elastomer business grew to about 7% of total revenues in Q1 2025 [11] - AnnexOne revenues contributed approximately 200 basis points to total revenues, exceeding expectations [14] - The company anticipates a high single-digit growth rate in biologics HVP components in the second half of 2025 [13] Company Strategy and Development Direction - The company is focused on capitalizing on competitive strengths and improving overall margins [41] - There is a twofold strategy for the HVP delivery devices business, focusing on margin improvement and evaluating the best path forward [16] - The company is transitioning towards drug handling in contract manufacturing, which is expected to have higher margins and lower capital intensity [19][107] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand outlook, noting an increase in demand as the year progresses [61][138] - The company is monitoring tariff impacts and has implemented programs to mitigate expenses [59][120] - Management indicated that the first quarter's strength offsets some tariff headwinds, and they expect to see a ramp-up in demand in the second half of 2025 [35][138] Other Important Information - The company announced executive leadership changes, including the departure of the CFO and the appointment of a new Senior Vice President [20][22] - The company is increasing its full-year 2025 revenue guidance to a range of $2.945 billion to $2.975 billion [34] - Capital expenditures for 2025 are guided at $275 million, unchanged from prior guidance [39] Q&A Session Summary Question: Utilization assumptions for the new site in Dublin - Management indicated that utilization is currently low and incorporated into guidance, with ramp-up expected throughout the year [46] Question: Margin improvements in delivery devices - Management noted better efficiencies in the E and PC business and improvements in contract manufacturing margins [48] Question: Guidance on high-value product growth - Management explained that pricing is slightly lower than anticipated and there are short-term supply constraints affecting growth [54] Question: Impact of tariffs and geopolitical factors - Management stated that they do not see significant demand impacts from government spending reductions and are implementing measures to mitigate tariff expenses [59] Question: Demand visibility and order trends - Management confirmed that order patterns are consistent with expectations and anticipate a sequential improvement throughout the year [138] Question: Pricing benefits related to SmartDose - Management clarified that no pricing benefits from SmartDose are embedded in guidance at this time [121] Question: Operating margin guidance - Management did not provide specific operating margin guidance but indicated that they are targeting a return to higher margins over time [124]